Synergism between PGE1-metabolites(13,14-dihydro-prostaglandin E1, 15-keto prostaglandin E1, 15-keto-13,14-dihydro-prostaglandin E1) and nitric oxide (NO) on platelet aggregation.

[1]  R. Katzenschlager,et al.  Interaction between prostaglandin E1 and nitric oxide (NO). , 1991, Thrombosis research.

[2]  C. Diehm,et al.  Formation of 13,14-dihydro-prostaglandin E1 during intravenous infusions of prostaglandin E1 in patients with peripheral arterial occlusive disease. , 1991, Prostaglandins.

[3]  S. Moncada,et al.  Vascular endothelial cells synthesize nitric oxide from L-arginine , 1988, Nature.

[4]  J. Vane,et al.  Receptor-mediated release of endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells is coupled. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[5]  S Moncada,et al.  The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. , 1987, Biochemical and biophysical research communications.

[6]  S. Moncada,et al.  The anti‐aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide , 1987, British journal of pharmacology.

[7]  S. Moncada,et al.  Comparative pharmacology of endothelium‐derived relaxing factor, nitric oxide and prostacyclin in platelets , 1987, British journal of pharmacology.

[8]  S. Moncada,et al.  Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor , 1987, Nature.

[9]  L. Ignarro,et al.  Inhibition of human platelet aggregation by S-nitrosothiols. Heme-dependent activation of soluble guanylate cyclase and stimulation of cyclic GMP accumulation. , 1983, Molecular pharmacology.

[10]  R. Furchgott,et al.  The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine , 1980, Nature.

[11]  J. Vane,et al.  Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets. , 1977, Prostaglandins.

[12]  A. Olsson,et al.  INTRAVENOUS PROSTAGLANDIN E1 IN SEVERE PERIPHERAL VASCULAR DISEASE , 1976, The Lancet.

[13]  J. Westwick.  The effect of pulmonary metabolites of prostaglandins E1, E2 and F2alpha on ADP-induced aggregation of human and rabbit platelets [proceedings]. , 1976, British journal of pharmacology.

[14]  J. Vane,et al.  An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation , 1976, Nature.

[15]  R. Horton,et al.  Metabolism of prostaglandins A1 and E1 in man. , 1975, The Journal of clinical investigation.

[16]  L. Carlson,et al.  Femoral-artery infusion of prostaglandin E 1 in severe peripheral vascular disease. , 1973, Lancet.

[17]  M. Hamberg,et al.  On the Metabolism of Prostaglandins E1 and E2 in Man , 1971 .

[18]  E. Änggård.  The Biological Activities of Three Metabolites of Prostaglandin E1 , 1966 .

[19]  G. Born,et al.  Aggregation of Blood Platelets by Adenosine Diphosphate and its Reversal , 1962, Nature.

[20]  S. Rundqvist,et al.  The isolation of prostaglandin F from sheep prostate glands. , 1960 .